Recap: Exact Sciences Q4 Earnings

Shares of Exact Sciences EXAS fell in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 59.46% over the past year to ($0.15), which beat the estimate of ($0.22).

Revenue of $466,339,000 higher by 57.77% year over year, which beat the estimate of $446,220,000.

Looking Ahead

Exact Sciences Q4 Adj EPS $(0.15) Beats $(0.22) Est., Sales $466.30M Beat $446.22M Estimate

Details Of The Call

Date: Feb 16, 2021

Time: 05:00 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.exactsciences.com%2F&eventid=2947790&sessionid=1&key=7A6EAD362F45519771EB10F00535B95F&regTag=&V2=false&sourcepage=register

Recent Stock Performance

Company's 52-week high was at $159.54

52-week low: $35.25

Price action over last quarter: Up 14.49%

Company Overview

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!